A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : CG / cisplatin/gemcitabine

[Related PubMed/MEDLINE]
Total Number of Papers: 17
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   CG  (>> Co-occurring Abbreviation)
Long Form:   cisplatin/gemcitabine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Modulation of biliary cancer chemo-resistance through microRNA-mediated rewiring of the expansion of CD133+ cells. BTC, miR
2019 Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM). AEs, aUC, CI, CR, HR, ORR, PFS, VG
2013 A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. EGFR TKI, ICER, NSCLC, PFS, QALYs
2012 Nedaplatin/Gemcitabine Versus Carboplatin/Gemcitabine in Treatment of Advanced Non-small Cell Lung Cancer: A Randomized Clinical Trial. NG, NSCLC, ORR, OS, PFS
2012 Retrospective analysis of clinical outcomes with neoadjuvant cisplatin-based regimens for muscle-invasive bladder cancer. DI, MIBC, OS
2011 Carboplatin and gemcitabine combination in metastatic triple-negative anthracycline- and taxane-pretreated breast cancer patients: a phase II study. ORR, TNBC
2011 Ethnic difference in hematological toxicity in patients with non-small cell lung cancer treated with chemotherapy: a pooled analysis on Asian versus non-Asian in phase II and III clinical trials. CP, CV, NSCLC
2011 Quality of life, geriatric assessment and survival in elderly patients with non-small-cell lung cancer treated with carboplatin-gemcitabine or carboplatin-paclitaxel: NVALT-3 a phase III study. CGA, CP, NSCLC, PC, PS, QOL
2010 Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial. CP, EA, NSCLC
10  2010 Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer. CP, NSCLC, PS
11  2009 Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. NSCLC, OS, PFS
12  2008 Paclitaxel and gemcitabine versus carboplatin and gemcitabine in patients with advanced non-small-cell lung cancer. A phase III study of the Hellenic Cooperative Oncology Group. CI, OR, OS
13  2007 A retrospective analysis of malignant pleural mesothelioma patients treated either with chemotherapy or best supportive care between 1990 and 2005 A single institution experience. BSC, CMI, CT, DMPM
14  2007 Cisplatin plus gemcitabine with or without vinorelbine as induction chemotherapy prior to radical locoregional treatment for patients with stage III non-small-cell lung cancer (NSCLC): results of a prospective randomized study. LT, NSCLC
15  2006 Sequential chemotherapy with cisplatin/gemcitabine (CG) followed by mitoxantrone/methotrexate/mitomycin (MMM) in patients with malignant pleural mesothelioma. A multicenter Italian Phase II Study (SITMP1). CRs, MMM, MPM, ORR, OS, PD, PRs, SD, TTP
16  2004 Cardiotoxicity in advanced non-small cell lung cancer patients treated with platinum and non-platinum based combinations as first-line treatment. EG, LVEF, MUGA, NSCLC
17  2003 First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial. EG, QOL